OQS
IGMS

Occudo Quantitative Strategies’s IGM Biosciences IGMS Stock Holding History

Occudo Quantitative Strategies’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-27,408
Closed -$733K – 1246
2022
Q1 		$733K Buy
+27,408
New +$510K 0.06% 494

Other funds holding IGMS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Occudo Quantitative Strategies's IGMS Position: Q2 2022 in Review

Occudo Quantitative Strategies sold out of IGM Biosciences (IGMS) in Q2 2022, closing a stake of 27,408 shares — an estimated $733K sold.

Occudo Quantitative Strategies first reported a position in IGMS in Q1 2022 and held it in 1 quarter. The position peaked at $733K in Q1 2022. 89 funds tracked by Wall St. Rank hold IGMS as of Q2 2022.

  • Occudo Quantitative Strategies reported no remaining IGM Biosciences position as of Q2 2022 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 27,408 IGM Biosciences shares in Q2 2022, an estimated $733K.
  • Occudo Quantitative Strategies first reported a position in IGM Biosciences in Q1 2022 and held it in 1 quarter.
  • Occudo Quantitative Strategies's IGM Biosciences position peaked at $733K in Q1 2022.
  • 89 funds tracked by Wall St. Rank held IGM Biosciences as of Q2 2022.

Based on Occudo Quantitative Strategies's 13F filing for Q2 2022, filed 15 Aug 2022.